U.S. Markets closed

Illumina, Inc. (ILMN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
191.20-2.95 (-1.52%)
At close: 4:00PM EDT

191.20 0.00 (0.00%)
After hours: 4:50PM EDT

People also watch
ALXNREGNBIIBVRTXCELG

Illumina, Inc.

5200 Illumina Way
San Diego, CA 92122
United States
858-202-4500
http://www.illumina.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees5,500

Key Executives

NameTitlePayExercisedAge
Mr. Jay T. FlatleyExec. Chairman991.87k20.45M64
Mr. Francis A. deSouzaChief Exec. Officer, Pres and Director908.66kN/A46
Mr. Omead OstadanExec. VP of Operations, Products and Strategy539.95kN/A45
Dr. Mostafa Ronaghi Ph.D.Chief Technology Officer and Sr. VP451.24kN/A48
Mr. Marc A. StapleyChief Admin. Officer and Exec. VP556.47kN/A47
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company’s sequencing by synthesis technology provides researchers with various applications and the ability to sequence mammalian genomes. It also offers arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow for the detection of known genetic markers on a single array. In addition, the company provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and non-invasive prenatal testing services. It serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as through life-science distributors. It has collaboration agreements with IBM Watson Health to access genome data interpretation by integrating Watson for genomics into Illumina’s BaseSpace Sequence Hub and tumor sequencing process; and NRGene to develop new molecular breeding tools for cattle to support global food production. The company also has a co-development agreement with Munich Leukemia Laboratory GmbH and IBM Watson Health to build a cognitive technology prototype to help researchers improve leukemia treatment. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.

Corporate Governance

Illumina, Inc.’s ISS Governance QualityScore as of August 1, 2017 is 9. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.